We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ironwood will focus on commercializing its currently marketed products and the development of its gastrointestinal, gout and abdominal pain pipeline. It is expected to be profitable in 2019.
Ironwood Pharmaceuticals plans to split into two independent, publicly traded companies, spinning off some of its research and development work into a yet-unnamed business in the first half of 2019.